Key facts
- This page summarizes Albert Mitrani's Form 4 filing for Organicell Regenerative Medicine, Inc. (ZEOX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Nov 2021, 21:52.
Albert Mitrani - 29 Oct 2021 Form 4 Insider Report for Organicell Regenerative Medicine, Inc. (ZEOX)
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- ZEOX
- Reported as of
- 29 Oct 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Nov 2021, 21:52:28 UTC
- Prior SEC filing
- 21 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Albert Mitrani
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Albert Mitrani filed Form 4 for Organicell Regenerative Medicine, Inc. (ZEOX) on 02 Nov 2021.
Change
- Previous filing in this sequence was filed on 21 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCEL
transaction
Common Stock
Other
- Transaction value
- Shares
- -15,000,000
- Change %
- -9%
- Price
- Shares after
- 151,790,190
- Date
- 29 Oct 2021
- Ownership
- Direct
- Footnotes
- F1, F2
OCEL
transaction
Common Stock
Other
- Transaction value
- Shares
- +15,000,000
- Change %
- +9.9%
- Price
- Shares after
- 166,790,190
- Date
- 29 Oct 2021
- Ownership
- Direct
- Footnotes
- F1, F2
OCEL
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 116,707,890
- Date
- 29 Oct 2021
- Ownership
- Additional shares held by spouse
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares of common stock of Organicell Regenerative Medicine, Inc., a Nevada corporation (the "Company") were disposed of and acquired, respectively, pursuant to an Exchange Agreement dated October 29, 2021 (the "Agreement"), whereby the Reporting Person exchanged shares of common stock of the Company previously issued under the Organicell Regenerative Medicine, Inc. Management and Consultants Performance Stock Plan for shares of common stock of the Company in the Organicell Regenerative Medicine, Inc. 2021 Equity Incentive Plan. The newly issued shares shall vest on December 31, 2023.
Footnote F2
Received in exchange for the Company's common stock on a 1:1 basis. This exchange was completed in connection with the Agreement.
Footnote F3
The total number of shares of common stock owned collectively by Maria Ines Mitrani and Albert Mitrani is 283,498,080.